AUSTIN, Texas, Nov. 6, 2013 (GLOBE NEWSWIRE) -- LDR Holding Corporation (Nasdaq:LDRH), a global medical device company focused on designing and commercializing novel and proprietary surgical technologies for the treatment of patients suffering from spine disorders, today reported its financial results for the third quarter and nine months ended September 30, 2013.
Third Quarter 2013 Revenue Highlights
-
Total revenue for the quarter ended September 30, 2013 increased 29.8% to $27.2 million, compared to $20.9 million for the quarter ended September 30, 2012.
-
Revenue from exclusive technology products grew 36.7% to $22.9 million, compared to the third quarter of 2012.
-
Revenue in the United States increased 29.8% to $20.1 million, compared to $15.5 million in the third quarter of 2012, and represented 73.8% of total revenue.
- International revenue increased 29.8% for the third quarter of 2013 to $7.1 million, representing 26.2% of total revenue.
Total revenue for the third quarter of 2013 increased 29.8% to $27.2 million, compared to $20.9 million for the third quarter of 2012. LDR's revenue from exclusive technology products grew 36.7% to $22.9 million in the third quarter of 2013, while revenue from traditional fusion products increased 2.2% to $4.3 million. Revenue from LDR's exclusive lumbar products in the third quarter increased 57%, compared with the third quarter of 2012, in part due to the FDA approval of the Avenue L Lateral lumbar fusion interbody device that was introduced in the United States in September 2012. Additionally, revenue from the Company's exclusive cervical products grew 27% in the third quarter of 2013, compared with the third quarter of 2012.
Gross profit for the third quarter of 2013 was $23.1 million and gross margin was 84.9%, compared to a gross profit of $17.4 million and a gross margin of 82.9% for the third quarter of 2012. Gross margin was favorably impacted by a higher mix of exclusive technology products and geographic distribution.
For the nine months ended September 30, 2013, LDR's total revenue was $79.6 million, an increase of 21%, compared to $66.0 million for the same period a year ago. For this same period, revenue from LDR's exclusive technology products grew 25.4% to $65.4 million, while revenue from traditional fusion products increased 3.2% to $14.2 million.
Gross profit for the nine months ended September 30, 2013 was $67.1 million and gross margin was 84.2%, compared to a gross profit of $55.2 million and a gross margin of 83.8% for the same period in 2012. Gross margin was favorably impacted by a higher mix of exclusive technology products and geographic distribution.
Christophe Lavigne, President and Chief Executive Officer of LDR Holding, commented, "We are pleased with our accomplishments to date, marked by the FDA Premarket Approval (PMA) in August for Mobi-C®, the first and only cervical disc replacement device to receive FDA approval to treat both one-level and two-level cervical disc disease. Based on results of an FDA pivotal clinical trial which enrolled 575 patients, Mobi-C® is the only cervical disc technology to demonstrate overall clinical superiority as compared to two-level traditional fusion. This is an outstanding accomplishment for LDR which validates our research and development strategies and our commitment to provide highly innovative products to surgeons and patients around the world. We look forward to leveraging our clinical and commercial knowledge based on over 17,000 Mobi-C® implantations completed in international markets to date."
On a geographic basis, for the third quarter of 2013, LDR's revenue in the United States increased 29.8% to $20.1 million, compared to $15.5 million in the third quarter of 2012, and represented 73.8% of total revenue. LDR's international revenue increased 29.8% for the third quarter of 2013 to $7.1 million, representing 26.2% of total revenue.
For the nine months ended September 30, 2013, LDR's revenue in the United States increased 23.0% to $57.5 million, compared to $46.7 million for the same period a year ago. International revenue increased 15.1% to $22.2 million, compared to $19.3 million for the same period a year ago.
Net loss for the third quarter of 2013 totaled $8.0 million, or $1.68 per share, which included $4.7 million in noncash expenses associated with the revaluation of warrants leading up to the IPO, compared to a net loss of $3.1 million, or $0.66 per share, for the same quarter a year ago. After reflecting the increase in shares outstanding and other transactions that resulted from the Company's IPO, pro forma net loss for the third quarter of 2013 totaled $6.8 million, or $0.29 per pro forma diluted share.
For the nine months ended September 30, 2013, net loss totaled $12.8 million, or $2.72 per diluted share, which included $5.6 million in noncash expenses associated with the revaluation of warrants leading up to the IPO, compared to a net loss of $7.3 million, or $1.58 per diluted share, for the same period a year ago. After reflecting the increase in shares outstanding and other transactions that resulted from the Company's IPO, pro forma net loss for the nine months ended September 30, 2013, totaled $9.4 million, or $0.40 per pro forma diluted share.
Adjusted EBITDA for the third quarter of 2013 was $(0.1) million, compared to an adjusted EBITDA of $(0.3) million for the third quarter of 2012. For the nine months ended September 30, 2013, adjusted EBITDA was $1.5 million, compared to an adjusted EBITDA of $0.6 million for the same period a year ago.
Mr. Lavigne added, "We believe that our highly differentiated technologies that focus on surgeon and patient needs, our participation in some of the fastest growing segments of the spine market and our investments in sales and marketing infrastructure enhance LDR's competitive position and growth profile."
Balance Sheet and Liquidity
As of September 30, 2013, LDR had $11.6 million in cash and cash equivalents, $10.3 million in working capital and $53.2 million in debt. Subsequent to the close of the quarter, LDR completed an initial public offering of its common stock that closed on October 15, 2013. In the IPO, LDR raised net proceeds of approximately $77.0 million after the underwriting discount and offering expenses. Information on the use of the proceeds of the Company's IPO was contained in the prospectus filed with the Securities and Exchange Commission on October 8, 2013.
Conference Call
LDR Holding Corporation will host a conference call today at 5:00 p.m. Eastern Time to discuss its third quarter 2013 financial results. The conference call will be available to interested parties through a live audio webcast available through LDR's website at www.ldr.com. Those without internet access may join the call from within the United States by dialing (877) 312-5637; outside the United States, by dialing (253) 237-1149.
A telephone replay will be available for two weeks following the call by dialing (855) 859-2056 for domestic participants and (404) 537-3406 for international participants. When prompted, please enter the replay pin number 90494072. For those who are not available to listen to the live webcast, the call will be archived for 90 days on LDR Holding's website.
Forward-Looking Statements
This press release contains statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief or current expectations of LDR and members of its management team with respect to LDR's future business operations as well as the assumptions upon which such statements are based. Forward-looking statements include specifically, but are not limited to, LDR's market opportunities, growth, future products, market acceptance of its products, sales and financial results and such statements are subject to risks and uncertainties such as the timing and success of new product introductions, physician acceptance, endorsement, and use of LDR's products, regulatory matters, competitor activities, changes in and adoption of reimbursement rates, potential product recalls, effects of global economic conditions and changes in foreign currency exchange rates. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found in LDR's Risk Factors disclosure in its Registration Statement on Form S-1/A, dated October 8, 2013, and in LDR's other filings with the SEC. LDR disclaims any responsibility to update any forward-looking statements.
About LDR Holding Corporation
LDR Holding Corporation is a global medical device company focused on designing and commercializing novel and proprietary surgical technologies for the treatment of patients suffering from spine disorders. LDR's primary products are based on its exclusive VerteBRIDGE® fusion and Mobi® non-fusion technology platforms and are designed for applications in the cervical and lumbar spine. These technologies enable products that are less invasive, provide greater intra-operative flexibility, offer simplified surgical techniques and promote improved clinical outcomes for patients as compared to existing alternatives. LDR recently received approval from the U.S. Food and Drug Administration (FDA) for the Mobi-C® cervical disc replacement device, the first and only cervical disc replacement device to receive FDA approval to treat both one-level and two-level cervical disc disease. For more information regarding LDR Holding, visit www.ldr.com.
Use of Non-GAAP Financial Measures
To supplement LDR's consolidated financial statements prepared in accordance with U.S. generally accepted accounting principles (GAAP), LDR uses certain non-GAAP financial measures in this release, including adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) and adjusted EBITDA. A reconciliation of the non-GAAP financial measures used in this release to the most comparable U.S. GAAP measures for the respective periods can be found in a table later in this release immediately following the condensed consolidated statements of cash flows.
Management defines EBITDA as net income (loss) plus interest (income) expense, net, income tax expense and depreciation and amortization. Management defines Adjusted EBITDA as EBITDA plus stock-based compensation expense and change in fair value of common stock warrants. The Company presents Adjusted EBITDA because management believes it is a useful indicator of operating performance. LDR's management uses Adjusted EBITDA principally as a measure of operating performance and believes that Adjusted EBITDA is useful to investors because it is frequently used by securities analysts, investors and other interested parties in their evaluation of the operating performance of companies in industries similar to LDR. Management also uses Adjusted EBITDA for planning purposes, including the preparation of the annual operating budget and financial projections.
Adjusted EBITDA should not be considered in isolation or as a substitute for a measure of the Company's liquidity or operating performance prepared in accordance with GAAP and is not indicative of net income (loss) from operations as determined under GAAP. Adjusted EBITDA and other non-GAAP financial measures have limitations that should be considered before using these measures to evaluate the Company's liquidity or financial performance. Adjusted EBITDA does not include certain expenses that may be necessary to review LDR's operating results and liquidity requirements. Management's definition and calculation of Adjusted EBITDA may differ from that of other companies.
| LDR HOLDING CORPORATION AND SUBSIDIARIES | ||
| CONDENSED CONSOLIDATED BALANCE SHEETS | ||
| (in thousands, except share and per share amounts) | ||
|
September 30, 2013 |
December 31, 2012 |
|
| Unaudited | ||
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $ 11,632 | $ 19,135 |
| Accounts receivable, net | 18,640 | 16,309 |
| Inventory, net | 16,108 | 16,772 |
| Other current assets | 4,355 | 3,768 |
| Prepaid expenses | 2,401 | 806 |
| Total current assets | 53,136 | 56,790 |
| Property and equipment, net | 12,261 | 12,296 |
| Goodwill | 6,621 | 6,621 |
| Intangible assets, net | 2,742 | 2,619 |
| Restricted cash | 2,000 | 2,000 |
| Related party notes receivable | — | 270 |
| Deferred tax assets | 539 | 554 |
| Other assets | 354 | 441 |
| Total assets | $ 77,653 | $ 81,591 |
| LIABILITIES, REDEEMABLE PREFERRED STOCK AND STOCKHOLDERS' DEFICIT | ||
| Current liabilities: | ||
| Current portion of long-term debt | $ 1,900 | $ 1,903 |
| Line of credit, net of discount | 18,215 | — |
| Current portion of capital lease payable | 14 | 32 |
| Accounts payable | 6,276 | 7,855 |
| Accrued expenses | 13,102 | 10,727 |
| Short-term financing | 2,747 | 1,772 |
| Deferred tax liabilities | 533 | 542 |
| Total current liabilities | 42,787 | 22,831 |
| Line of credit, net of discount | — | 18,985 |
| Long-term debt, net of discount and current portion | 30,363 | 30,326 |
| Warrant liability | 9,760 | 4,167 |
| Long-term capital lease payable, net of current portion | 8 | 9 |
| Other long-term liabilities | 1,922 | 904 |
| Total liabilities | 84,840 | 77,222 |
| Commitments and contingencies | ||
| Series C redeemable convertible preferred stock | 35,000 | 35,000 |
| Stockholders' deficit: | ||
| Series A-1 convertible preferred stock | 11 | 11 |
| Series A-2 convertible preferred stock | 18 | 18 |
| Series B convertible preferred stock | 15 | 15 |
| Common stock | 5 | 5 |
| Additional paid-in capital | 26,332 | 25,603 |
| Accumulated other comprehensive loss | 88 | (457) |
| Accumulated deficit | (68,656) | (55,826) |
| Total stockholders' deficit | (42,187) | (30,631) |
| Total liabilities, redeemable preferred stock and stockholders' deficit | $ 77,653 | $ 81,591 |
| LDR HOLDING CORPORATION AND SUBSIDIARIES | ||||
| CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS | ||||
| (in thousands, except per share amounts) | ||||
| (Unaudited) | ||||
|
Three Months Ended September 30, |
Nine Months Ended September 30, |
|||
| 2013 | 2012 | 2013 | 2012 | |
| Revenue | $ 27,195 | $ 20,948 | $ 79,616 | $ 65,952 |
| Cost of goods sold | 4,093 | 3,577 | 12,561 | 10,709 |
| Gross profit | 23,102 | 17,371 | 67,055 | 55,243 |
| Operating expenses: | ||||
| Research and development | 2,473 | 2,252 | 7,215 | 8,537 |
| Sales and marketing | 16,810 | 12,440 | 47,761 | 37,478 |
| General and administrative | 4,725 | 3,443 | 13,498 | 10,682 |
| Total operating expenses | 24,008 | 18,135 | 68,474 | 56,697 |
| Operating income (loss) | (906) | (764) | (1,419) | (1,454) |
| Other operating income (expense): | ||||
| Other income (expense) | (523) | (420) | (478) | (464) |
| Interest income | 3 | 12 | 10 | 20 |
| Interest expense | (1,516) | (1,409) | (4,379) | (3,216) |
| Change in fair value of common stock warrants | (4,739) | (235) | (5,593) | (1,458) |
| Total other income (expense), net | (6,775) | (2,052) | (10,440) | (5,118) |
| Loss before income taxes | (7,681) | (2,816) | (11,859) | (6,572) |
| Income tax expense | (303) | (234) | (971) | (703) |
| Net loss | (7,984) | (3,050) | (12,830) | (7,275) |
| Other comprehensive income ( loss): | ||||
| Foreign currency translation | 984 | 545 | 545 | 24 |
| Comprehensive loss | $ (7,000) | $ (2,505) | $ (12,285) | $ (7,251) |
| Net loss per common share: | ||||
| Basic and diluted | $ (1.68) | $ (0.66) | $ (2.72) | $ (1.58) |
| Weighted average number of shares outstanding: | ||||
| Basic and diluted | 4,754,997 | 4,616,916 | 4,721,601 | 4,610,710 |
| Pro forma net loss per share: | ||||
| Basic and diluted | $ (0.34) | $ (0.55) | ||
| Weighted average number of shares used in computing pro forma net loss per share: | ||||
| Basic and diluted | 23,422,862 | 23,389,466 | ||
| LDR HOLDING CORPORATION AND SUBSIDIARIES | ||||
| CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS | ||||
| (in thousands) | ||||
| (Unaudited) | ||||
|
Three Months Ended September 30, |
Nine Months Ended September 30, |
|||
| 2013 | 2012 | 2013 | 2012 | |
| Operating activities: | ||||
| Net loss | (7,984) | (3,050) | (12,830) | (7,275) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||
| Bad debt expense | 141 | 332 | 375 | 332 |
| Provision for excess and obsolete inventories | 222 | 333 | 789 | 848 |
| Depreciation and amortization | 1,010 | 810 | 2,930 | 2,264 |
| Stock-based compensation | 350 | 77 | 498 | 214 |
| Accretion related to warrants and discounts on long-term debt | 506 | 497 | 1,353 | 901 |
| Change in fair value of common stock warrants | 4,739 | 235 | 5,593 | 1,458 |
| Deferred income tax benefit | — | — | — | — |
| Loss on disposal of assets | 13 | 25 | 38 | 99 |
| Unrealized foreign currency loss (gains) | 515 | 446 | 415 | 365 |
| Changes in operating assets and liabilities: | ||||
| Cash restricted for line of credit agreement | — | — | — | (1,000) |
| Accounts receivable | 161 | 676 | (2,675) | (2,292) |
| Prepaid expenses and other current assets | (1,544) | 249 | (2,013) | 197 |
| Inventory | 114 | (673) | 29 | (3,973) |
| Other assets | 283 | 32 | 341 | 42 |
| Accounts payable | (286) | (923) | (1,730) | 155 |
| Accrued expenses | 935 | 339 | 2,285 | 2,394 |
| Other long-term liabilities | 348 | 490 | 1,030 | 546 |
| Net cash used in operating activities | (477) | (105) | (3,572) | (4,725) |
| Investing activities: | ||||
| Proceeds from sale of property and equipment | — | 31 | 53 | 31 |
| Purchase of intangible assets | (144) | (193) | (374) | (550) |
| Purchase of property and equipment | (1,334) | (1,976) | (2,613) | (4,186) |
| Net cash used in investing activities | (1,478) | (2,138) | (2,934) | (4,705) |
| Financing activities: | ||||
| Exercise of stock options | 8 | (2) | 175 | 132 |
| Payments on capital leases | (4) | (26) | (16) | (156) |
| Net proceeds (payments) on short-term financings | (116) | (11) | 921 | 435 |
| Proceeds from line of credit | — | — | — | 2,800 |
| Payments from line of credit | (778) | — | (778) | — |
| Proceeds from long-term debt | — | — | — | 15,000 |
| Payments on long-term debt | (474) | (390) | (1,408) | (4,225) |
| Debt issuance costs | — | — | — | (144) |
| Proceeds from issuance of common stock | — | 9 | — | 9 |
| Proceeds from exercise of preferred stock warrants | — | — | — | — |
| Net cash used in financing activities | (1,364) | (420) | (1,106) | 13,851 |
| Effect of exchange rate on cash | 154 | (60) | 109 | (184) |
| Net change in cash and cash equivalents | (3,165) | (2,723) | (7,503) | 4,237 |
| Cash and cash equivalents, beginning of period | 14,797 | 12,559 | 19,135 | 5,599 |
| Cash and cash equivalents, end of period | 11,632 | 9,836 | 11,632 | 9,836 |
| LDR HOLDING CORPORATION AND SUBSIDIARIES | ||||
| RECONCILIATION OF NET LOSS TO NON-GAAP FINANCIAL MEASURES | ||||
| (in thousands, except per share amounts) | ||||
| (Unaudited) | ||||
|
Three Months Ended September 30, |
Nine Months Ended September 30, |
|||
| 2013 | 2012 | 2013 | 2012 | |
| Revenue, as reported | $ 27,195 | $ 20,948 | $ 79,616 | $ 65,952 |
| Net loss, as reported | $ (7,984) | $ (3,050) | $ (12,830) | $ (7,275) |
| Interest income | (3) | (12) | (10) | (20) |
| Interest expense | 1,516 | 1,409 | 4,379 | 3,216 |
| Income tax expense | 303 | 234 | 971 | 703 |
| Depreciation and amortization | 1,010 | 810 | 2,930 | 2,264 |
| Subtotal non-GAAP EBITDA | (5,158) | (609) | (4,560) | (1,112) |
| Change in fair value of common stock warrants | 4,739 | 235 | 5,593 | 1,458 |
| Share-based compensation | 350 | 77 | 498 | 214 |
| Non-GAAP adjusted EBITDA | $ (69.0) | $ (297.0) | $ 1,531.0 | $ 560.0 |
| Non-GAAP adjusted EBITDA margin | —% | (1)% | 2% | 1% |
| LDR HOLDING CORPORATION AND SUBSIDIARIES | ||
| RECONCILIATION OF GAAP NET LOSS PER SHARE TO PRO FORMA NET LOSS PER SHARE | ||
| (in thousands) | ||
| (Unaudited) | ||
|
Three Months Ended September 30, 2013 |
Nine Months Ended September 30, 2013 |
|
| Numerator | ||
| GAAP net loss attributable to common stockholders | $ (7,984) | $ (12,830) |
| Interest expense for convertible notes that converted to common shares upon the IPO | 833 | 2,318 |
| Interest expense for loan facility that was paid in full with the proceeds from the IPO | 380 | 1,130 |
| Pro forma net loss | $ (6,771) | $ (9,382) |
| Denominator | ||
| GAAP weighted average shares outstanding - basic and diluted | 4,755 | 4,722 |
| Conversion of preferred stock upon the IPO | 10,978 | 10,978 |
| Conversion of convertible notes upon the IPO | 1,929 | 1,929 |
| Common shares issued in the IPO | 5,750 | 5,750 |
| Common shares issued in the exercise of the preferred stock warrant during the IPO | 11 | 11 |
| Weighted average number of shares used in computing pro forma net loss per share - basic and diluted | 23,423 | 23,390 |
| Pro forma net loss per share - basic and diluted | $ (0.29) | $ (0.40) |